Sangamo BioSciences Inc. (NASDAQ:SGMO) shot up 4.1% during mid-day trading on Thursday . The company traded as high as $5.86 and last traded at $5.86, with a volume of 331,513 shares traded. The stock had previously closed at $5.63.

A number of brokerages have issued reports on SGMO. Zacks Investment Research cut Sangamo BioSciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 5th. Jefferies Group reaffirmed a “buy” rating and set a $14.00 target price on shares of Sangamo BioSciences in a research report on Thursday, June 9th. Wedbush reaffirmed an “outperform” rating and set a $30.00 target price on shares of Sangamo BioSciences in a research report on Friday, May 6th. Finally, Wells Fargo & Co. began coverage on Sangamo BioSciences in a research report on Tuesday, May 3rd. They set a “buy” rating for the company. Two investment analysts have rated the stock with a sell rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $16.75.

The company has a 50-day moving average price of $6.08 and a 200 day moving average price of $6.16. The firm’s market capitalization is $412.38 million.

Sangamo BioSciences (NASDAQ:SGMO) last announced its earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.01. During the same period in the prior year, the business posted ($0.08) EPS. The firm earned $3.94 million during the quarter, compared to analyst estimates of $5.49 million. The firm’s quarterly revenue was down 70.8% compared to the same quarter last year. Equities research analysts anticipate that Sangamo BioSciences Inc. will post ($0.98) EPS for the current year.

A hedge fund recently raised its stake in Sangamo BioSciences stock. Royce & Associates LLC boosted its position in shares of Sangamo BioSciences Inc. (NASDAQ:SGMO) by 47.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 312,100 shares of the biopharmaceutical company’s stock after buying an additional 100,000 shares during the period. Royce & Associates LLC owned 0.45% of Sangamo BioSciences worth $2,849,000 as of its most recent filing with the SEC.

Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.